Evozyne builds generative AI models and a platform to design therapeutic proteins and accelerate drug development. The company collaborated with NVIDIA earlier in the year to develop an AI model for designing therapeutic proteins, aiming to exponentially increase the number and quality of synthetic protein designs. Evozyne says this approach could enable new therapeutics and reduce development time for treatments. The company intends to use the new funding to advance its generative AI-powered drug discovery platform and product development. Evozyne was founded in 2020 and is led by CEO Mike Gamson. It is based in Chicago, IL.

Total raised

$81M

Funding rounds

1

Latest round

Series B

Latest activity

Sep 2023